Clinical Trials Logo
  1. Home
  2. Chronic Renal Failure
  3. NCT00878033
  4. Details
NCT00878033 Clinical Trial

Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients

Chronic Renal Failure Clinical Trial

Official title:
Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00878033
Other study ID # UKH-KIMII-001-09
Secondary ID
Status Completed
Phase N/A
First received April 7, 2009
Last updated March 9, 2017
Start date April 2009
Est. completion date December 2010

Study information
Verified date March 2017
Source Martin-Luther-Universität Halle-Wittenberg
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study investigates the relationship between autonomic dysfunction and chronic inflammation in hemodialysis patients.

Recruitment information / eligibility
Status Completed
Enrollment 45
Est. completion date December 2010
Est. primary completion date October 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chronic Kidney Disease Stadium KDIGO 5D for at leat 3 months on Dialysis

- Age >18 years

- Sinus action in EKG

- Patient capable for informed consent

- Written and signed informed consent

Exclusion Criteria:

- Clinical overt signs of infections of any kind

- Active malign disease

- CRP levels above 50 mg/L

- Cardiac Pace Maker

- Atrial Fibrillation

- Refusal of informed consent

- Cardiac Transplantation

- Immunosuppressive medication

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Germany Martin-Luther-Universität Halle-Wittenberg, Dept. of Internal Medicine II Halle (Saale) Saxony-Anhalt

Sponsors (1)
Lead Sponsor Collaborator
Martin-Luther-Universität Halle-Wittenberg

Country where clinical trial is conducted

Germany, 

See also
  Status Clinical Trial Phase
Recruiting NCT02565459 - MSC and Kidney Transplant Tolerance (Phase A) Phase 1
Recruiting NCT01876017 - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Phase 1/Phase 2
Recruiting NCT02356419 - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics Phase 1
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Completed NCT02047006 - Dose-finding of Rivaroxaban in Hemodialysis Phase 4
Completed NCT01617824 - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes Phase 4
Completed NCT00828776 - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Phase 2/Phase 3
Completed NCT00597753 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Terminated NCT00372489 - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Phase 2
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00228436 - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Phase 2
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Completed NCT01879618 - Use Of Fragmin In Hemodialysis Phase 3
Not yet recruiting NCT01346215 - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure Phase 3
Completed NCT01220843 - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease Phase 3
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00598273 - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Phase 3
Completed NCT00597584 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3

External Links